RTTNews BiotechCodex · 实盘不做把握 5/10
北京时间·🕒 发布 07-09 11:37:31时区推断·⟳ 抓取 07-11 21:19:56回填·⚡ 决策 07-13 02:02:51·107.0 天前
Rhythm的Setmelanotide获NEJM发表但核心疗效与FDA获批已是旧信息
本次只是TRANSCEND三期结果在NEJM发表，正文同时说明FDA已于2026年3月批准该适应症，核心商业化催化早已发生。
📄 原文RTTNews Biotech↗ 原文
Rhythms' TRANSCEND Trial Published In NEJM Shows BMI Reduction In Acquired Hypothalamic Obesity
Rhythm Pharmaceuticals, Inc. (RYTM), announced that results from its pivotal Phase 3 TRANSCEND trial of Setmelanotide i…
不做 Rhythm Pharmaceuticals（RYTM.US）
论文发表不等于新增审批或销售超预期，且FDA批准已在2026年3月发生，抓取时已偏旧，短线没有可回测的新增edge。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-09 · 扩散 medium · price-in 风险 high ↗
关键理由
- 本次只是TRANSCEND三期结果在NEJM发表，正文同时说明FDA已于2026年3月批准该适应症，核心商业化催化早已发生。
- RTTNews抓取距事件已超过86小时，且正文价格显示消息发布时股价已接近一年高位，短线新鲜度不足。
- 没有新增审批、销售指引、定价、报销或患者渗透数据，无法形成新的收入/利润增量重估。
主要风险
- 若后续公司披露IMCIVREE在 acquired hypothalamic obesity 的处方放量、报销覆盖或销售超预期，需重新评估。
原文全文
展开原文 · 2,263 字
Rhythm Pharmaceuticals, Inc. (RYTM), announced that results from its pivotal Phase 3 TRANSCEND trial of Setmelanotide in patients with acquired hypothalamic obesity have been published in The New England Journal of Medicine (NEJM).
Acquired hypothalamic obesity is a rare condition that can occur following hypothalamic injury, leading to accelerated and sustained weight gain. Patients often face limited treatment options, making effective therapies a critical need.
The TRANSCEND study, the largest and longest placebo-controlled trial conducted in this patient population, enrolled adults and children aged four years and older. Over 52 weeks, patients treated with Setmelanotide achieved a placebo-adjusted BMI reduction of 19.8%, with a mean BMI decrease of 16.5% compared to a 3.3% increase in the placebo group. Notably, 80% of treated patients achieved at least a 5% BMI reduction, alongside clinically meaningful improvements in hunger.
In March 2026, the U.S. FDA approved Setmelanotide (IMCIVREE) as the first and only therapy for acquired hypothalamic obesity in adults and children aged four years and older. The European Medicines Agency also recommended marketing authorization for this indication.
Dr. Christian Roth, senior author and pediatric endocrinologist at Seattle Children's Research Institute, emphasized the importance of these findings, noting the consistent reductions in BMI and hunger as potentially transformative for patients and families living with hypothalamic obesity.
RYTM has traded between $74.50 and $122.20 over the past year. The stock closed Wednesday's trading at $114.43, down 0.03%. During after-hours trading the stock is at $114.46, up 0.03%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 03, 2026 16:09 ET A busy week for economic data saw the release of several reports on the labor market and the manufacturing sector. In the U.S., the jobs report for June was in focus and results of the latest ISM purchasing managers’ survey threw light on the health of the factory sector. In Europe, results of the PMI surveys gained attention while the unemployment figures from Germany were also in news. Similarly in Asia, survey data on the Chinese manufacturing sector was the highlight.
Acquired hypothalamic obesity is a rare condition that can occur following hypothalamic injury, leading to accelerated and sustained weight gain. Patients often face limited treatment options, making effective therapies a critical need.
The TRANSCEND study, the largest and longest placebo-controlled trial conducted in this patient population, enrolled adults and children aged four years and older. Over 52 weeks, patients treated with Setmelanotide achieved a placebo-adjusted BMI reduction of 19.8%, with a mean BMI decrease of 16.5% compared to a 3.3% increase in the placebo group. Notably, 80% of treated patients achieved at least a 5% BMI reduction, alongside clinically meaningful improvements in hunger.
In March 2026, the U.S. FDA approved Setmelanotide (IMCIVREE) as the first and only therapy for acquired hypothalamic obesity in adults and children aged four years and older. The European Medicines Agency also recommended marketing authorization for this indication.
Dr. Christian Roth, senior author and pediatric endocrinologist at Seattle Children's Research Institute, emphasized the importance of these findings, noting the consistent reductions in BMI and hunger as potentially transformative for patients and families living with hypothalamic obesity.
RYTM has traded between $74.50 and $122.20 over the past year. The stock closed Wednesday's trading at $114.43, down 0.03%. During after-hours trading the stock is at $114.46, up 0.03%.
For comments and feedback contact: editorial@rttnews.com
Business News
July 03, 2026 16:09 ET A busy week for economic data saw the release of several reports on the labor market and the manufacturing sector. In the U.S., the jobs report for June was in focus and results of the latest ISM purchasing managers’ survey threw light on the health of the factory sector. In Europe, results of the PMI surveys gained attention while the unemployment figures from Germany were also in news. Similarly in Asia, survey data on the Chinese manufacturing sector was the highlight.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。